Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Europe Cystic Fibrosis Therapeutics Market Forecast 2020-2028

Published by Inkwood Research Product code 927063
Published Content info 102 Pages
Delivery time: 2-3 business days
Price
Back to Top
Europe Cystic Fibrosis Therapeutics Market Forecast 2020-2028
Published: March 2, 2020 Content info: 102 Pages
Description

KEY FINDINGS

The cystic fibrosis therapeutics market of Europe is anticipated to register a CAGR of 10.10% over the projected period of 2020-2028. Europe has the largest market share in the global market in terms of revenue. A rise in the incidence of cystic fibrosis has given rise to the need for newer and advanced therapeutics for its treatment leading to an increase in the number of pipeline drugs, which is expected to create opportunities for market expansion in the region.

MARKET INSIGHTS

In order to survey the strong growth of the European cystic fibrosis market further, the region is segmented into France, Belgium, Russia, Poland, the United Kingdom, Germany, Italy, and the rest of Europe that includes countries such as Finland, Bulgaria, Sweden, Greece, Switzerland, Spain, Portugal, and Czech Republic. In Russia, although the government provides insurance for cystic fibrosis, it does not cover all medications and treatments. Only 'Pulmozyme' is covered at the federal level, which is hindering the market growth, and hence implying the Russian market will grow at a steady rate. In countries like Belgium, the rising incidences of cystic fibrosis across the country and initiating reimbursement is expected to propel the market growth. In Poland, CF may have a considerable impact on healthcare expenditures due to direct healthcare costs and low productivity, despite its low prevalence. Poland's healthcare expenditure rose to 6.5% of GDP in 2016 from 6.3% in 2015. Hence, the high cost of cystic fibrosis treatment, together with increasing healthcare expenditure, is estimated to propel the market in Poland.

COMPETITIVE INSIGHTS

Abbott Laboratories, GlaxoSmithKline PLC, F. Hoffmann-La Roche Ltd, Novartis International AG, Agilent Technologies, Inc, etc. are some of the renowned companies operating in the region.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
Table of Contents
Product Code: 29832

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. MARKET DEFINITION
  • 3.2. KEY DRIVERS
    • 3.2.1. ADVANCEMENTS IN THE CYSTIC FIBROSIS THERAPEUTICS TREATMENT
    • 3.2.2. INCREASING INCIDENCE OF CYSTIC FIBROSIS (CF)
    • 3.2.3. RISE IN THE R&D OF NOVEL CYSTIC FIBROSIS THERAPEUTICS
  • 3.3. KEY RESTRAINTS
    • 3.3.1. STRINGENT REGULATION
    • 3.3.2. LOW AWARENESS AMONG DEVELOPING ECONOMIES

4. KEY ANALYTICS

  • 4.1. PORTER'S FIVE FORCE ANALYSIS
    • 4.1.1. THREAT OF NEW ENTRY
    • 4.1.2. THREAT OF SUBSTITUTION
    • 4.1.3. BUYER'S POWER
    • 4.1.4. SUPPLIER'S POWER
    • 4.1.5. COMPETITIVE RIVALRY
  • 4.2. PESTEL ANALYSIS
  • 4.3. OPPORTUNITY MATRIX
  • 4.4. VENDOR LANDSCAPE
  • 4.5. KEY INVESTMENT INSIGHTS

5. MARKET BY ROUTE OF ADMINISTRATION

  • 5.1. INHALE
  • 5.2. ORAL

6. MARKET BY DRUG CLASS

  • 6.1. CFTR MODULATORS
  • 6.2. BRONCHODILATORS
  • 6.3. MUCOLYTIC
  • 6.4. PANCREATIC ENZYME SUPPLEMENTS

7. GEOGRAPHICAL ANALYSIS

  • 7.1. EUROPE
    • 7.1.1. THE UNITED KINGDOM
    • 7.1.2. FRANCE
    • 7.1.3. GERMANY
    • 7.1.4. ITALY
    • 7.1.5. RUSSIA
    • 7.1.6. BELGIUM
    • 7.1.7. POLAND
    • 7.1.8. REST OF EUROPE

8. COMPANY PROFILES

  • 8.1. ABBOTT LABORATORIES
  • 8.2. ABBVIE INC
  • 8.3. AGILENT TECHNOLOGIES INC
  • 8.4. ALLERGAN PLC
  • 8.5. F. HOFFMANN-LA ROCHE
  • 8.6. GILEAD SCIENCES INC
  • 8.7. GLAXOSMITHKLINE PLC
  • 8.8. JOHNSON & JOHNSON
  • 8.9. MYLAN N.V
  • 8.10. NOVARTIS AG
  • 8.11. PERKINELMER
  • 8.12. PFIZER INC
  • 8.13. PHARMAXIS LTD
  • 8.14. TEVA PHARMACEUTICAL INDUSTRIES LTD
  • 8.15. VERTEX PHARMACEUTICALS INCORPORATED

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - VETERINARY VACCINE
  • TABLE 2: EUROPE CYSTIC FIBROSIS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, HISTORICAL YEARS, 2016 -2019 (IN $ MILLION)
  • TABLE 3: EUROPE CYSTIC FIBROSIS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 4: EUROPE INHALE MARKET, HISTORICAL YEARS, 2016 -2019 (IN $ MILLION)
  • TABLE 5: EUROPE INHALE MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 6: EUROPE ORAL MARKET, HISTORICAL YEARS, 2016 -2019 (IN $ MILLION)
  • TABLE 7: EUROPE ORAL MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 8: EUROPE CYSTIC FIBROSIS THERAPEUTICS, BY DRUG CLASS, HISTORICAL YEARS, 2016 -2019 (IN $ MILLION)
  • TABLE 9: EUROPE CYSTIC FIBROSIS THERAPEUTICS, BY DRUG CLASS, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 10: EUROPE CFTR MODULATORS MARKET, HISTORICAL YEARS, 2016 -2019 (IN $ MILLION)
  • TABLE 11: LIST OF CFTR MODULATORS GENERIC AND BRAND NAME
  • TABLE 12: EUROPE CFTR MODULATORS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 13: EUROPE BRONCHODILATORS MARKET, HISTORICAL YEARS, 2016 -2019 (IN $ MILLION)
  • TABLE 14: LIST OF BRONCHODILATORS GENERIC AND BRAND NAME
  • TABLE 15: EUROPE BRONCHODILATORS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 16: EUROPE MUCOLYTIC MARKET, HISTORICAL YEARS, 2016 -2019 (IN $ MILLION)
  • TABLE 17: LIST OF MUCOLYTICS GENERIC AND BRAND NAME
  • TABLE 18: EUROPE MUCOLYTIC MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 19: EUROPE PANCREATIC ENZYME SUPPLEMENTS MARKET, HISTORICAL YEARS, 2016 -2019 (IN $ MILLION)
  • TABLE 20: EUROPE PANCREATIC ENZYME SUPPLEMENTS MARKET, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 21: EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016 -2019 (IN $ MILLION)
  • TABLE 22: EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION):

LIST OF FIGURES

  • FIGURE 1: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 2: OPPORTUNITY MATRIX
  • FIGURE 3: VENDOR LANDSCAPE
  • FIGURE 4: KEY INVESTMENT INSIGHTS
  • FIGURE 5: EUROPE CYSTIC FIBROSIS THERAPEUTICS, BY ROUTE OF ADMINISTRATION, IN 2019
  • FIGURE 6: EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, BY INHALE, 2020-2028 (IN $ MILLION)
  • FIGURE 7: EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, BY ORAL, 2020-2028 (IN $ MILLION)
  • FIGURE 8: EUROPE CYSTIC FIBROSIS THERAPEUTICS, BY DRUG CLASS, IN 2019
  • FIGURE 9: EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, BY CFTR MODULATORS, 2020-2028 (IN $ MILLION)
  • FIGURE 10: EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, BY BRONCHODILATORS, 2020-2028 (IN $ MILLION)
  • FIGURE 11: EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, BY MUCOLYTIC, 2020-2028 (IN $ MILLION)
  • FIGURE 12: EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, BY PANCREATIC ENZYME SUPPLEMENTS, 2020-2028 (IN $ MILLION)
  • FIGURE 13: EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 14: THE UNITED KINGDOM CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 15: FRANCE CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 16: GERMANY CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 17: ITALY CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 18: RUSSIA CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 19: BELGIUM CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 20: POLAND CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 21: REST OF EUROPE CYSTIC FIBROSIS THERAPEUTICS MARKET, 2020-2028 (IN $ MILLION)
Back to Top